Many people on these weight-loss drugs - which include Ozempic, Wegovy, Zepbound and Mounjaro ... even though some have faced declines in their stock prices at times attributable to such concerns.

Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...

Novo Nordisk (NVO) stock slipped after ate-stage trial data for a higher-dose version of its popular obesity therapy, ...

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...

The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...

Amycretin could give Novo a buzzy product in a newly competitive obesity market. It works similarly to existing GLP-1 ...

In this photo illustration, the injectable weight-loss medication Wegovy is available at New City Halstead Pharmacy on April 24, 2024 in Chicago. Scott Olson/Getty Images, FILE Officials were ...

which includes Novo Nordisk's (NOVOb.CO), opens new tab blockbuster weight-loss drug Wegovy. Here's what Wall Street analysts say about the inclusion: WHAT IT MEANS FOR PATIENTS The potential for ...

Both Wegovy ... Novo’s stock fell slightly in early December after a trial sponsored by Lilly found that patients who took Zepbound lost 20.2% of their body weight, on average, compared with ...